Canada Markets closed

(MNPR)

. Currency in USD
Add to watchlist
- (-)
Full screen
Trade prices are not sourced from all markets
Previous Close2.8100
Open2.8100
BidN/A x N/A
AskN/A x N/A
Day's Range2.3600 - 2.8100
52 Week Range2.3600 - 17.0100
Volume28,853
Avg. VolumeN/A
Market Cap33.239M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.7020
Earnings DateMar. 23, 2022 - Mar. 28, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est28.40
  • GlobeNewswire

    Monopar to Present at the H.C. Wainwright BioConnect Conference

    WILMETTE, Ill., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced that Chandler Robinson, MD, Monopar’s Chief Executive Officer, will present at the H.C. Wainwright BioConnect Conference. The presentation will be available for on-demand viewing starting on Monday, January 10, 2022 at 7:00am

  • GlobeNewswire

    Monopar Advances Dosing of Camsirubicin to Higher Level Than Tested In Any Previous Clinical Trial

    WILMETTE, Ill., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced the positive recommendation from its safety review committee to escalate to the second dose level in its camsirubicin Phase 1b trial in patients with advanced soft tissue sarcoma (ASTS). This decision was made following a revi

  • GlobeNewswire

    Monopar Therapeutics Reports Third Quarter 2021 Financial Results and Recent Clinical Developments

    First Patients Dosed in Camsirubicin Phase 1b Clinical Trial in U.S.Validive® Phase 2b/3 VOICE Trial Cleared to Enroll in Europe andon Track for Reaching Interim in H1 2022 WILMETTE, Ill., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Monopar or the Company) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced third quarter 2021 financial